In order to reduce the harm caused by XRCC2 overexpression, based on the CGGA RNA-seq dataset we identified small molecules that target XRCC2 that have the potential clinical application of improving the status of glioma treatment and the prognosis of glioma patients. This evidence concerns the gene XRCC2 and central nervous system cancer.